Cyclacel Pharmaceuticals, Inc. (CYCC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

1.3800

-0.0200

(-1.43%)

At close: 04:00PM EDT

1.4100

+0.03

(+2.17%)

After hours:

07:54PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Inside Bar (Bearish)

View all chart patterns

Performance Outlook

Previous Close	1.4000
Open	1.4000
Bid	1.3800 x 1000
Ask	1.4000 x 1200
Day's Range	1.3400 - 1.4399
52 Week Range	1.0500 - 6.6400
Volume	891,572
Avg. Volume	282,840

Market Cap	13.793M
Beta (5Y Monthly)	1.41
PE Ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CYCC

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Cyclacel Pharmaceuticals, Inc.
Analyst Report: Bristol-Myers Squibb CompanyBristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Rating
Fair Value
Economic Moat
2 days agoMorningstar